Hispanic stroke patients less likely to receive clot-busting drugs in

Hispanic stroke patients admitted to hospitals in the border states of California, Arizona, New Mexico and Texas were less likely than non-Hispanics in the same border states to receive clot-busting drugs and more likely to die, according to research presented at the American Stroke Association's International Stroke Conference 2014.

Researchers analyzed for Hispanic and non-Hispanic patients according to demographics and clinical characteristics in states bordering Mexico and states not on the Mexican border. They found:

  • Of the nearly 35,000 Hispanic stroke patients, 21,130 were admitted in border states and 13,774 in non-border states.
  • Only 4.8 percent of Hispanic patients in border state hospitals received clot-busting drugs compared to 5.7 percent of non-Hispanic patients in border state hospitals.
  • Hispanic stroke patients were 30 percent more likely than non-Hispanics to die in border state hospitals.
  • There was no notable difference in death rates between Hispanic and non-Hispanic stroke patients in non-border state hospitals. Researchers say more study is needed to determine why clot-busters are underutilized in Hispanics admitted in border states but not in other states.

add to favorites email to friend print save as pdf

Related Stories

Sleep apnea common among stroke-related brainstem injuries

Feb 12, 2014

People whose brainstems are affected by their stroke have a significantly higher prevalence of sleep apnea than those who have stroke-related injury elsewhere in the brain, according to research presented at the American ...

Clot busters limit stroke damage despite age; stroke severity

Feb 13, 2014

Regardless of a patient's age, or severity of stroke, prompt treatment with a clot-busting drug limited stroke-related disability, according to late-breaking science presented at the American Stroke Association's International ...

Recommended for you

Correction of cardiovascular symptoms of MPS I in animal model

55 minutes ago

REGENXBIO Inc. today announced that gene transfer mediated by REGENXBIO's NAV AAV8 vectors resulted in sustained serum α-L-iduronidase (IDUA) expression, as well as correction of systemic features of MPS I, or Hurler syndrome, ...

Researchers explain 38-year-old mystery of the heart

14 hours ago

In a new study published in Proceedings of the National Academy of Sciences, researchers at the University of Alberta's Faculty of Medicine & Dentistry have explained how the function of a key protein in the ...

User comments